Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

@article{Mandelli2009DaunorubicinVM,
  title={Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.},
  author={Franco Mandelli and Marco Vignetti and Stefan Suciu and Roberto Stasi and Maria-Concetta Petti and Giovanna Meloni and Petra Muus and Filippo Marmont and Jean-Pierre Marie and Boris Labar and Xavier Thomas and Francesco Di Raimondo and R. Willemze and Vincenzo Liso and Felicetto Ferrara and Liliana Baila and Paola Fazi and Robert A Zittoun and S. Amadori and Theo de Witte},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 32},
  pages={
          5397-403
        }
}
PURPOSE To compare the antitumor efficacy of three different anthracyclines in combination with cytarabine and etoposide in adult patients with newly diagnosed acute myeloid leukemia (AML). PATIENTS AND METHODS We randomly assigned 2,157 patients (age range, 15 to 60 years) to receive intensive induction-consolidation chemotherapy containing either daunorubicin, idarubicin, or mitoxantrone. After achieving complete remission (CR), patients were assigned to undergo either allogeneic or… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 71 CITATIONS

Acute myeloid leukemia--major progress over four decades and glimpses into the future.

  • American journal of hematology
  • 2016
VIEW 23 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

Acute Myeloid Leukaemia

VIEW 6 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia

  • Mediterranean journal of hematology and infectious diseases
  • 2019
VIEW 2 EXCERPTS
CITES RESULTS & METHODS

FILTER CITATIONS BY YEAR

2010
2019

CITATION STATISTICS

  • 6 Highly Influenced Citations

  • Averaged 4 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

in complete remission correlates with relapse risk : Results of the EORTC - GIMEMA AML - 10 trial

S Fujimoto, M Ogawa
  • leukemia
  • 2003

Acute myeloid leukemia.

  • The New England journal of medicine
  • 1999
VIEW 1 EXCERPT

Daunorubicin versus mitoxantrone as induction for AML in younger adults given intensive chemotherapy: Preliminary results of MRC AML-12 Trial

AK Burnett, AH Goldstone, DW Milligan
  • Br J Haematol 105:67a,
  • 1999

Similar Papers

Loading similar papers…